FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Praćenje interakcija lekova kod starijih pacijenata sa benignom hiperplazijom prostate i kardiovaskularnim oboljenjima

Monitoring of drug interactions in elderly patients with benign prostatic hyperplasia and cardiovascular diseases

Thumbnail
2022
bitstream_11635.pdf (181.5Kb)
Authors
Lazarević, Katarina
Marković, Aleksandra
Vezmar-Kovačević, Sandra
Jovanović, Marija
Ćulafić, Milica
Kovačević, Milena
Vučićević, Katarina
Miljković, Branislava
Conference object (Published version)
Metadata
Show full item record
Abstract
Benigna hiperplazija prostate (BHP) predstavlja nekancerozno uvećanje prostate povezano sa simptomima donjeg urinarnog trakta i spada u najčešća oboljenja starijih muškaraca. Kako su u ovom dobu uobičajeni komorbiditeti, pre svega kardiovaskularna (KVS) oboljenja, može se očekivati veliki broj klinički značajnih interakcija lekova. Svrha ove studije bila je analiza učestalosti i vrste potencijalnih interakcija u terapiji starijih pacijenata sa BHP i KVS oboljenjem. Sprovedeno retrospektivno istraživanje uključilo je 93 muškaraca starijih od 65 godina, obolelih od BHP i hipertenzije ili nekog KVS oboljenja. Podaci o pacijentima su prikupljani iz medicinske dokumentacije. Potencijalne interakcije su identifikovane i procenjivane korišćenjem Lexicomp® elektronske baze podataka. Deskriptivna analiza je obavljena u programu Microsoft ® Office Excel 2010. Prosečna starost ispitanika iznosila je 75,3±6,05. Broj lekova u terapiji bio je u rasponu od 2 do 13. Pet ili više lekova prim...enjivalo je 72,04% pacijenata. Detektovano je ukupno 509 interakcija, od kojih čak 467 spada u klinički značajne (C, D, X). Najveći broj identifikovanih interakcija pripada klasi C (85,46%), dok je 4,91% iz klase D, a samo 1,38% iz klase X. U okviru klase X, koja ukazuje da treba izbegavati istovremenu primenu kombinacije lekova, najčešće se javljala interakcija između dva α-blokatora. Zabeleženo je 412 farmakodinamskih i 47 farmakokinetičkih interakcija. Dvojni mehanizam je detektovan kod 29 interakcija, a 21 se odvijao nepoznatim mehanizmom. Rezultati studije upućuju da uključivanje farmaceuta u praćenje pacijenata sa BHP može biti korisno, imajući u vidu značajan broj identifikovanih klinički značajnih interakcija.

Benign prostatic hyperplasia (BPH) represents a non-cancerous prostate enlargement associated with lower urinary tract symptoms and is one of the most common diseases in older men. As comorbidities, primarily cardiovascular diseases (CVD) are common in this age group, a great number of clinically significant drug interactions can be expected. The aim of this research was to estimate the frequency and type of potential interactions in the treatment of elderly with BPH and CVD. A retrospective study included 93 men aged over 65 with BPH and hypertension or CVD. Patients’ data were collected from medical records. Potential interactions were identified and assessed using the Lexicomp ® database. Descriptive analysis was performed in Microsoft® Office Excel 2010. Patients’ average age was 75.3±6.05. The number of drugs in therapy ranged from 2 to 13. Five or more drugs were used by 72.04% of the patients. A total of 509 interactions were detected, of which 467 are clinically sign...ificant (C, D, X). Most interactions belonged to category C (85.46%), while 4.91% belonged to class D, and only 1.38% to class X. Within class X, which indicates that concomitant use of drugs should be avoided, the interaction between the two α-blockers was most frequent. 412 pharmacodynamic and 47 pharmacokinetic interactions were identified. The dual mechanism was detected in 29 interactions, while for 21 the mechanism was unknown. The obtained results suggest the involvement of pharmacists in the monitoring of patients with BPH may be useful, given the great proportion of identified clinically significant interactions.

Source:
Arhiv za farmaciju, 2022, 72, 4-suplement, S278-S279
Publisher:
  • Savez farmaceutskih udruženja Srbije (SFUS)
Note:
  • VIII Kongres farmaceuta Srbije sa međunarodnim učešćem, 12-15.10.2022, Beograd
[ Google Scholar ]
Handle
https://hdl.handle.net/21.15107/rcub_farfar_4389
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/4389
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - CONF
AU  - Lazarević, Katarina
AU  - Marković, Aleksandra
AU  - Vezmar-Kovačević, Sandra
AU  - Jovanović, Marija
AU  - Ćulafić, Milica
AU  - Kovačević, Milena
AU  - Vučićević, Katarina
AU  - Miljković, Branislava
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4389
AB  - Benigna hiperplazija prostate (BHP) predstavlja nekancerozno uvećanje prostate
povezano sa simptomima donjeg urinarnog trakta i spada u najčešća oboljenja starijih
muškaraca. Kako su u ovom dobu uobičajeni komorbiditeti, pre svega kardiovaskularna
(KVS) oboljenja, može se očekivati veliki broj klinički značajnih interakcija lekova. Svrha ove
studije bila je analiza učestalosti i vrste potencijalnih interakcija u terapiji starijih pacijenata
sa BHP i KVS oboljenjem. Sprovedeno retrospektivno istraživanje uključilo je 93 muškaraca
starijih od 65 godina, obolelih od BHP i hipertenzije ili nekog KVS oboljenja. Podaci o
pacijentima su prikupljani iz medicinske dokumentacije. Potencijalne interakcije su
identifikovane i procenjivane korišćenjem Lexicomp® elektronske baze podataka.
Deskriptivna analiza je obavljena u programu Microsoft ® Office Excel 2010. Prosečna starost
ispitanika iznosila je 75,3±6,05. Broj lekova u terapiji bio je u rasponu od 2 do 13. Pet ili više
lekova primenjivalo je 72,04% pacijenata. Detektovano je ukupno 509 interakcija, od kojih
čak 467 spada u klinički značajne (C, D, X). Najveći broj identifikovanih interakcija pripada
klasi C (85,46%), dok je 4,91% iz klase D, a samo 1,38% iz klase X. U okviru klase X, koja
ukazuje da treba izbegavati istovremenu primenu kombinacije lekova, najčešće se javljala
interakcija između dva α-blokatora. Zabeleženo je 412 farmakodinamskih i 47
farmakokinetičkih interakcija. Dvojni mehanizam je detektovan kod 29 interakcija, a 21 se
odvijao nepoznatim mehanizmom. Rezultati studije upućuju da uključivanje farmaceuta u
praćenje pacijenata sa BHP može biti korisno, imajući u vidu značajan broj identifikovanih
klinički značajnih interakcija.
AB  - Benign prostatic hyperplasia (BPH) represents a non-cancerous prostate enlargement
associated with lower urinary tract symptoms and is one of the most common diseases in
older men. As comorbidities, primarily cardiovascular diseases (CVD) are common in this
age group, a great number of clinically significant drug interactions can be expected. The aim
of this research was to estimate the frequency and type of potential interactions in the
treatment of elderly with BPH and CVD. A retrospective study included 93 men aged over 65
with BPH and hypertension or CVD. Patients’ data were collected from medical records.
Potential interactions were identified and assessed using the Lexicomp ® database.
Descriptive analysis was performed in Microsoft® Office Excel 2010. Patients’ average age
was 75.3±6.05. The number of drugs in therapy ranged from 2 to 13. Five or more drugs
were used by 72.04% of the patients. A total of 509 interactions were detected, of which 467
are clinically significant (C, D, X). Most interactions belonged to category C (85.46%), while
4.91% belonged to class D, and only 1.38% to class X. Within class X, which indicates that
concomitant use of drugs should be avoided, the interaction between the two α-blockers was
most frequent. 412 pharmacodynamic and 47 pharmacokinetic interactions were identified.
The dual mechanism was detected in 29 interactions, while for 21 the mechanism was
unknown. The obtained results suggest the involvement of pharmacists in the monitoring of
patients with BPH may be useful, given the great proportion of identified clinically significant
interactions.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Praćenje interakcija lekova kod starijih pacijenata sa benignom hiperplazijom prostate i kardiovaskularnim oboljenjima
T1  - Monitoring of drug interactions in elderly patients with benign prostatic hyperplasia and cardiovascular diseases
VL  - 72
IS  - 4-suplement
SP  - S278
EP  - S279
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4389
ER  - 
@conference{
author = "Lazarević, Katarina and Marković, Aleksandra and Vezmar-Kovačević, Sandra and Jovanović, Marija and Ćulafić, Milica and Kovačević, Milena and Vučićević, Katarina and Miljković, Branislava",
year = "2022",
abstract = "Benigna hiperplazija prostate (BHP) predstavlja nekancerozno uvećanje prostate
povezano sa simptomima donjeg urinarnog trakta i spada u najčešća oboljenja starijih
muškaraca. Kako su u ovom dobu uobičajeni komorbiditeti, pre svega kardiovaskularna
(KVS) oboljenja, može se očekivati veliki broj klinički značajnih interakcija lekova. Svrha ove
studije bila je analiza učestalosti i vrste potencijalnih interakcija u terapiji starijih pacijenata
sa BHP i KVS oboljenjem. Sprovedeno retrospektivno istraživanje uključilo je 93 muškaraca
starijih od 65 godina, obolelih od BHP i hipertenzije ili nekog KVS oboljenja. Podaci o
pacijentima su prikupljani iz medicinske dokumentacije. Potencijalne interakcije su
identifikovane i procenjivane korišćenjem Lexicomp® elektronske baze podataka.
Deskriptivna analiza je obavljena u programu Microsoft ® Office Excel 2010. Prosečna starost
ispitanika iznosila je 75,3±6,05. Broj lekova u terapiji bio je u rasponu od 2 do 13. Pet ili više
lekova primenjivalo je 72,04% pacijenata. Detektovano je ukupno 509 interakcija, od kojih
čak 467 spada u klinički značajne (C, D, X). Najveći broj identifikovanih interakcija pripada
klasi C (85,46%), dok je 4,91% iz klase D, a samo 1,38% iz klase X. U okviru klase X, koja
ukazuje da treba izbegavati istovremenu primenu kombinacije lekova, najčešće se javljala
interakcija između dva α-blokatora. Zabeleženo je 412 farmakodinamskih i 47
farmakokinetičkih interakcija. Dvojni mehanizam je detektovan kod 29 interakcija, a 21 se
odvijao nepoznatim mehanizmom. Rezultati studije upućuju da uključivanje farmaceuta u
praćenje pacijenata sa BHP može biti korisno, imajući u vidu značajan broj identifikovanih
klinički značajnih interakcija., Benign prostatic hyperplasia (BPH) represents a non-cancerous prostate enlargement
associated with lower urinary tract symptoms and is one of the most common diseases in
older men. As comorbidities, primarily cardiovascular diseases (CVD) are common in this
age group, a great number of clinically significant drug interactions can be expected. The aim
of this research was to estimate the frequency and type of potential interactions in the
treatment of elderly with BPH and CVD. A retrospective study included 93 men aged over 65
with BPH and hypertension or CVD. Patients’ data were collected from medical records.
Potential interactions were identified and assessed using the Lexicomp ® database.
Descriptive analysis was performed in Microsoft® Office Excel 2010. Patients’ average age
was 75.3±6.05. The number of drugs in therapy ranged from 2 to 13. Five or more drugs
were used by 72.04% of the patients. A total of 509 interactions were detected, of which 467
are clinically significant (C, D, X). Most interactions belonged to category C (85.46%), while
4.91% belonged to class D, and only 1.38% to class X. Within class X, which indicates that
concomitant use of drugs should be avoided, the interaction between the two α-blockers was
most frequent. 412 pharmacodynamic and 47 pharmacokinetic interactions were identified.
The dual mechanism was detected in 29 interactions, while for 21 the mechanism was
unknown. The obtained results suggest the involvement of pharmacists in the monitoring of
patients with BPH may be useful, given the great proportion of identified clinically significant
interactions.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Praćenje interakcija lekova kod starijih pacijenata sa benignom hiperplazijom prostate i kardiovaskularnim oboljenjima, Monitoring of drug interactions in elderly patients with benign prostatic hyperplasia and cardiovascular diseases",
volume = "72",
number = "4-suplement",
pages = "S278-S279",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4389"
}
Lazarević, K., Marković, A., Vezmar-Kovačević, S., Jovanović, M., Ćulafić, M., Kovačević, M., Vučićević, K.,& Miljković, B.. (2022). Praćenje interakcija lekova kod starijih pacijenata sa benignom hiperplazijom prostate i kardiovaskularnim oboljenjima. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4-suplement), S278-S279.
https://hdl.handle.net/21.15107/rcub_farfar_4389
Lazarević K, Marković A, Vezmar-Kovačević S, Jovanović M, Ćulafić M, Kovačević M, Vučićević K, Miljković B. Praćenje interakcija lekova kod starijih pacijenata sa benignom hiperplazijom prostate i kardiovaskularnim oboljenjima. in Arhiv za farmaciju. 2022;72(4-suplement):S278-S279.
https://hdl.handle.net/21.15107/rcub_farfar_4389 .
Lazarević, Katarina, Marković, Aleksandra, Vezmar-Kovačević, Sandra, Jovanović, Marija, Ćulafić, Milica, Kovačević, Milena, Vučićević, Katarina, Miljković, Branislava, "Praćenje interakcija lekova kod starijih pacijenata sa benignom hiperplazijom prostate i kardiovaskularnim oboljenjima" in Arhiv za farmaciju, 72, no. 4-suplement (2022):S278-S279,
https://hdl.handle.net/21.15107/rcub_farfar_4389 .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB